Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Respiratory Research|August 25, 2019
Circulating neutrophils levels are a predictor of pneumonia risk in chronic obstructive pulmonary diseaseSteven J Pascoe, Alberto Papi, Dawn Midwinter, et al.International Journal of Chronic Obstructive Pulmonary Disease|February 15, 2018
The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the worldNeil Barnes, Takeo Ishii, Nobuyuki Hizawa, et al.Chest|July 25, 2014
Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropiumJean-Louis Pepin, John R Cockcroft, Dawn Midwinter, et al.International Journal of Chronic Obstructive Pulmonary Disease|January 15, 2021
Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial StiffnessBenjamin D Horne, Rehan Ali, Dawn Midwinter, et al.American Journal of Respiratory and Critical Care Medicine|November 10, 2015
Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled TrialIan S Stone, Neil C Barnes, Wai-Yee James, et al.International Journal of Chronic Obstructive Pulmonary Disease|July 2, 2020
Critical Error Frequency and the Impact of Training with Inhalers Commonly used for Maintenance Treatment in Chronic Obstructive Pulmonary DiseaseDavid J Collier, Pascal Wielders, Job van der Palen, et al.International Journal of Chronic Obstructive Pulmonary Disease|September 4, 2018
A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPDJob van der Palen, Wendy Moeskops-van Beurden, Carolyn M Dawson, et al.ERJ Open Research|November 14, 2019
Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study designSally Worsley, Neil Snowise, David M G Halpin, et al.Investigational New Drugs|September 22, 2010
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumorsMatthew D Galsky, Daniel D Von Hoff, Marcus Neubauer, et al.Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 14, 2022
Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT TrialJ Michael Wells, Gerard J Criner, David M G Halpin, et al.Pageof 2